申请人:Xu Lifeng
公开号:US20120178915A1
公开(公告)日:2012-07-12
This invention relates with the arylheterocycle-fused pyrimidines, derivatives and analogs of formula I:
or stereoisomers, tautoers, prodrugs, pharmaceutically acceptable salts, complex salts or solvates thereof, wherein:
A-cycle is of 3-8 saturated or unsaturated arylheterocycles or aliheterocyclic, containing 1-4 heteroatoms, B-cycle 5-8 member saturated or unsaturated heterocycle containing 1-4 heteroatoms; X
1
, X
2
, X
3
, X
4
are, independently at each occurrence, C, O, S, Se, N and P elements; R
1
, R
2
, R
3
is a substituent containing alicyclic group, arylcycle group, heterocyclic group, adamantane alkyl, adamantane heterocycle, adamantane analogs, sugar group, hydroxyl group, amino acid group or a combination of the above substituents.
This invention also relates with their preparative methods and applications.
该发明涉及与芳基杂环融合的嘧啶类化合物、衍生物和类似物的公式I:或其立体异构体、互变异构体、前药、药学上可接受的盐、复盐或溶剂化合物,其中:A环是由3-8个饱和或不饱和的芳基杂环或芳杂环组成,含有1-4个杂原子,B环是由5-8个成员的饱和或不饱和杂环组成,含有1-4个杂原子;X1、X2、X3、X4在每次出现时独立地是C、O、S、Se、N和P元素;R1、R2、R3是含有脂环基团、芳环基团、杂环基团、金刚烷烷基、金刚烷杂环、金刚烷类似物、糖基、羟基、氨基酸基团或上述基团的组合的取代基。该发明还涉及它们的制备方法和应用。